Neuroprotective and Therapeutic Strategies against Parkinson’s Disease: Recent Perspectives
Open accessThe DOI matches its Crossref record; 301 of the 301 references it cites were found in a registry or an index.
Abstract
Parkinsonism is a progressive motor disease that affects 1.5 million Americans and is the second most common neurodegenerative disease after Alzheimer’s. Typical neuropathological features of Parkinson’s disease (PD) include degeneration of dopaminergic neurons located in the pars compacta of the substantia nigra that project to the striatum (nigro-striatal pathway) and depositions of cytoplasmic fibrillary inclusions (Lewy bodies) which contain ubiquitin and α-synuclein. The cardinal motor signs of PD are tremors, rigidity, slow movement (bradykinesia), poor balance, and difficulty in walking (Parkinsonian gait). In addition to motor symptoms, non-motor symptoms that include autonomic and psychiatric as well as cognitive impairments are pressing issues that need to be addressed. Several different mechanisms play an important role in generation of Lewy bodies; endoplasmic reticulum (ER) stress induced unfolded proteins, neuroinflammation and eventual loss of dopaminergic neurons in the substantia nigra of mid brain in PD. Moreover, these diverse processes that result in PD make modeling of the disease and evaluation of therapeutics against this devastating disease difficult. Here, we will discuss diverse mechanisms that are involved in PD, neuroprotective and therapeutic strategies currently in clinical trial or in preclinical stages, and impart views about strategies that are promising to mitigate PD pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–301 of 301
Nishikawa, K., Li, H., Kawamura, R., Osaka, H., Wang, Y.-L., Hara, Y., Hirokawa, T., Manago, Y., Amano, T., Noda, M., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00555-2 · Cited by 158 · cited 1×
“On the other hand, UCH-L1 acts as an enzyme that recycles ubiquitin in neurons and destruction of UCH-L1 can lead to formation of misfolded proteins [77–79].”
BackgroundDoshi, P. K., Chhaya, N., & Bhatt, M. H. (2002) · Movement Disorders · doi:10.1002/mds.10198 · Cited by 157 · cited 1×
“Recent studies suggest that DBS may cause manic depression, induce emotional instability and suicidal thoughts [221,223,225–230].”
BackgroundBiopsies of olfactory epithelium in patients with Parkinson's disease
Witt, M., Bormann, K., Gudziol, V., Pehlke, K., Barth, K., Minovi, A., Hähner, A., Reichmann, H., & Hummel, T. (2009) · Movement Disorders · doi:10.1002/mds.22464 · Cited by 155 · cited 1×
“While a few studies suggest degeneration of olfactory epithelium of morphological change of olfactory bulb is the main reason of dopaminergic degeneration [255–257], others demonstrated that dopamine synthesizing neurons increased in the olfactory bulb, especially in the periglomerular region of patients inflicted wit…”
ResultGasmi, M., Herzog, C. D., Brandon, E. P., Cunningham, J. J., Ramirez, G. A., Ketchum, E. T., & Bartus, R. T. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300010 · Cited by 153 · cited 1×
“When the viral vector mediated method was used that delivered neurturin in the MPTP-treated monkey [157] or in 6-OHDA-treated rats [117], it protected against dopaminergic cell loss.”
MethodEtiology and Pathogenesis of Parkinson Disease
Schapira, A. H. V. (2009) · Neurologic Clinics · doi:10.1016/j.ncl.2009.04.004 · Cited by 150 · cited 1×
“To date, although several anti parkinsonian therapeutics showed promise in providing neuroprotective therapy against this devastating debilitating disorder in preclinical animal studies [31–33], none of them has been successful in humans.”
BackgroundSimuni, T., Jaggi, J. L., Mulholland, H., Hurtig, H. I., Colcher, A., Siderowf, A. D., Ravina, B., Skolnick, B. E., Goldstein, R., Stern, M. B., et al. (2002) · Journal of Neurosurgery · doi:10.3171/jns.2002.96.4.0666 · Cited by 147 · cited 1×
“Levodopa was introduced after it was demonstrated that main cause of PD is due to degeneration of dopaminergic neurons of the substantia nigra [4,5] and for the last several decades Levodopa prescription has been the standard therapy for PD patients although several complications have arisen since Levodopa can generat…”
BackgroundExplaining why Gleevec is a specific and potent inhibitor of Abl kinase
Lin, Y.-L., Meng, Y., Jiang, W., & Roux, B. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214330110 · Cited by 146
Diet, Urate, and Parkinson's Disease Risk in Men
Gao, X., Chen, H., Choi, H. K., Curhan, G., Schwarzschild, M. A., & Ascherio, A. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwm385 · Cited by 143
TREATMENT OF PARKINSONISM WITH BROMOCRIPTINE
Calne, D. B., Leigh, P. N., Teychenne, P. F., Bamji, A., & Greenacre, J. K. (1974) · The Lancet · doi:10.1016/s0140-6736(74)92219-3 · Cited by 138 · cited 1×
“Due to the complications associated with levodopa, new drugs in the form of dopamine receptor agonists have been developed for patients who have the early stages of PD; these dopamine receptor agonists confer anti-PD therapy with relatively low risk of developing dyskinesia [9–11].”
BackgroundNonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease
Hernán, M. A., Logroscino, G., & Rodríguez, L. A. G. (2006) · Neurology · doi:10.1212/01.wnl.0000204446.82823.28 · Cited by 137 · cited 1×
“It is important to note that recent epidemiological studies have demonstrated that certain NSAIDs and statins can significantly mitigate the risk of having PD [95–98].”
BackgroundNitrated Alpha-Synuclein and Microglial Neuroregulatory Activities
Reynolds, A. D., Kadiu, I., Garg, S. K., Glanzer, J. G., Nordgren, T. M., Ciborowski, P. S., Banerjee, R. V., & Gendelman, H. E. (2008) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-008-9100-z · Cited by 137 · cited 1×
“In in vitro studies, it has been recently been reported that different chemical conformation such as nitrated and aggregated forms of α-synuclein can induce microglial activation and eventually release more chemicals that are toxic to cells [88–91].”
BackgroundProgress in Stem Cell Therapy for Major Human Neurological Disorders
Martínez‐Morales, P., Revilla, A., Ocaña, I., González, C., Sainz, P., McGuire, D., & Liste, I. (2013) · Stem Cell Reviews and Reports · doi:10.1007/s12015-013-9443-6 · Cited by 134 · cited 1×
“Research demonstrated that generated iPSCs could be well differentiated into DA neurons of the midbrain, which subsequently have the ability to diminish motor symmetry in the 6-OHDA induced PD model [295].”
BackgroundSarkar, S., Chigurupati, S., Raymick, J. B., Mann, D., Bowyer, J. F., Schmitt, T., Beger, R. D., Hanig, J. P., Schmued, L. C., & Paule, M. G. (2014) · NeuroToxicology · doi:10.1016/j.neuro.2014.07.006 · Cited by 133
Self-citationDujardin, K., Blairy, S., Defebvre, L., Krystkowiak, P. C., Heß, U., Blond, S., & Destée, A. (2004) · PubMed · Cited by 131
Statin use and the risk of Parkinson disease
Wahner, A. D., Bronstein, J. M., Bordelon, Y. M., & Ritz, B. (2008) · Neurology · doi:10.1212/01.wnl.0000286942.14552.51 · Cited by 129 · cited 1×
“Subsequent epidemiological study has demonstrated that people who are taking simvastin can lower the risk of having PD [98,180].”
BackgroundGalván, A., Kuwajima, M., & Smith, Y. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.09.019 · Cited by 128
parkin counteracts symptoms in a Drosophila model of Parkinson's disease
Haywood, A. F., & Staveley, B. E. (2004) · BMC Neuroscience · doi:10.1186/1471-2202-5-14 · Cited by 128
Xiong, N., Zhang, Z., Huang, J., Chen, C., Zhang, Z., Jia, M., Xiong, J., Liu, X., Wang, F., Cao, X., et al. (2010) · Gene Therapy · doi:10.1038/gt.2010.152 · Cited by 123 · cited 1×
“MSC derived from the umbilical cord also shows neuroprotective ability in 6-OHDA models of PD [302,303].”
BackgroundSelley, M. L. (2005) · Brain Research · doi:10.1016/j.brainres.2004.02.083 · Cited by 121 · cited 2×
“It has been few decades since statins have been introduced in the medical field that are known to reduce cholesterol; however, they are also able to prevent inflammation associated with PD by inhibiting pro-inflammatory cytokines and free oxy radical production [178,179].”
BackgroundNovel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials
Kalia, L. V., Brotchie, J. M., & Fox, S. H. (2013) · Movement Disorders · doi:10.1002/mds.25273 · Cited by 119 · cited 1×
“However, additional therapies to L-DOPA, a reduction in motor function with adenosine A2A antagonism, balance and gait improvement with acetylcholine and noradrenaline and reduction of dyskinesia were observed when aimed at glutamatergic or serotonergic systems as these studies have indicated a major platform for non-…”
BackgroundOlfactory dysfunction as a diagnostic marker for Parkinson’s disease
Haehner, A., Hummel, T., & Reichmann, H. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.115 · Cited by 116 · cited 1×
“Therefore, olfactory testing used in conjunction with other biomarkers and imaging techniques may serve as a better tool for early detection of PD and thus earlier intervention with neuroprotective therapies before the emergence of extensive dopaminergic neuronal loss and motor symptoms [249,250,267].”
MethodParkin Gene Therapy for α-Synucleinopathy: A Rat Model of Parkinson's Disease
Yamada, M., Mizuno, Y., & Mochizuki, H. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.262 · Cited by 116
Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: A case-control study
Bower, J. H., Maraganore, D. M., Peterson, B. J., Ahlskog, J. E., & Rocca, W. A. (2006) · Neurology · doi:10.1212/01.wnl.0000227906.99570.cc · Cited by 113 · cited 1×
“It is important to note that recent epidemiological studies have demonstrated that certain NSAIDs and statins can significantly mitigate the risk of having PD [95–98].”
BackgroundMesenchymal stem cells and neuroregeneration in Parkinson's disease
Glavaski‐Joksimovic, A., & Bohn, M. C. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.03.016 · Cited by 111 · cited 1×
“In animal studies of PD, it has recently been demonstrated that MSCs can prevent DA degeneration and restore motor deficits [300].”
BackgroundTransgenic Models of α‐Synuclein Pathology: Past, Present, and Future
HASHIMOTO, M., ROCKENSTEIN, E., & MASLIAH, E. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07475.x · Cited by 108
Metabolomic analysis of urine and serum in Parkinson’s disease
Michell, A. W., Mosedale, D. E., Grainger, D. J., & Barker, R. A. (2008) · Metabolomics · doi:10.1007/s11306-008-0111-9 · Cited by 104
Parkin mediates the degradation‐independent ubiquitination of Hsp70
Moore, D. J., West, A. B., Dikeman, D. A., Dawson, V. L., & Dawson, T. M. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05261.x · Cited by 102
Olfactory dysfunction in essential tremor: A deficit unrelated to disease duration or severity
Louis, E. D., Bromley, S. M., Jurewicz, E. C., & Watner, D. (2002) · Neurology · doi:10.1212/01.wnl.0000033798.85208.f2 · Cited by 102
Mood changes with deep brain stimulation of STN and GPi: results of a pilot study
Okun, M. S. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.11.1584 · Cited by 101 · cited 1×
“Recent studies suggest that DBS may cause manic depression, induce emotional instability and suicidal thoughts [221,223,225–230].”
BackgroundParkin gene therapy for α-synucleinopathy : a rat model of Parkinson's disease
山田, 正. (2005) · Medical Entomology and Zoology · Cited by 101
Skin and platelet α-synuclein as peripheral biomarkers of Parkinson's disease
Michell, A. W., Luheshi, L. M., & Barker, R. A. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.02.030 · Cited by 100 · cited 1×
“This approach could be exploited to evaluate various diseases including Huntington’s [283].”
BackgroundUsing ‘omics’ to define pathogenesis and biomarkers of Parkinson’s disease
Caudle, W. M., Bammler, T. K., Lin, Y. S., Pan, S., & Zhang, J. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.54 · Cited by 99 · cited 1×
“An array of different, sensitive omics’ methods has been developed to identify relevant pathways for PD therapeutics [278,279].”
BackgroundThe application of NMR-based metabonomics in neurological disorders
Holmes, E. C., Tsang, T. M., & Tabrizi, S. J. (2006) · NeuroRx · doi:10.1016/j.nurx.2006.05.004 · Cited by 98
Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole
Carvey, P. M., Pieri, S., & Ling, Z. D. (1997) · Journal of Neural Transmission · doi:10.1007/bf01273182 · Cited by 97 · cited 1×
“It has been shown that the dopamine receptor agonist can protect against degeneration of TH neurons in both in vitro and in animal models [136–140].”
Rasagiline (TVP-1012): A new selective monoamine oxidase inhibitor for Parkinson's disease
Guay, D. R. P. (2006) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2006.12.001 · Cited by 97 · cited 1×
“Rasagiline, a selective monoamine oxidase B inhibitor, has also been promoted because of its potential for reducing symptoms but recently a wide variety of reported side effects are causing concern about the use of this medication [129].”
BackgroundThe Role of Anti-Inflammatory Agents in Parkinson???s Disease
McGeer, E. G., & McGeer, P. L. (2007) · CNS Drugs · doi:10.2165/00023210-200721100-00001 · Cited by 95 · cited 1×
“Although the underlying mechanism of microglial activation in PD not well elucidated, it is likely that the pro-inflammatory cytokines and toxic α-synuclein can activate microglia in the brain [81].”
BackgroundGuo, X., Dawson, V. L., & Dawson, T. M. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01542.x · Cited by 95 · cited 1×
“Neuroimmunophilins are proteins that have strong affinity to immunosuppressive drugs and also present in great amount in the brain and induce growth of the neurons [159–161].”
BackgroundNMDA antagonists partially protect against MPTP induced neurotoxicity in mice
Brouillet, E., & Beal, M. F. (1993) · Neuroreport · doi:10.1097/00001756-199304000-00011 · Cited by 93 · cited 1×
“When NMDA receptor antagonists were used in an MPTP induced model, it was found to be neuroprotective against dopaminergic cell loss in SN [103,104]; however, the antagonists have limited use due to its low potency and low tolerability.”
MethodES cell-derived renewable and functional midbrain dopaminergic progenitors
Chung, S., Moon, J.-I., Leung, A., Aldrich, D. P., Lukianov, S., Kitayama, Y., Park, S., Li, Y., Bolshakov, V. Y., Lamonerie, T., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016443108 · Cited by 93
Molecular Events Underlying Parkinson’s Disease – An Interwoven Tapestry
Lim, K., & Zhang, C. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00033 · Cited by 93
Maternal inheritance in Parkinson's disease
Wooten, G. F., Currie, L. J., Bennett, J. P., Harrison, M. B., Trugman, J. M., & Parker, W. D. (1997) · Annals of Neurology · doi:10.1002/ana.410410218 · Cited by 93 · cited 1×
“Although the exact mechanism of mitochondrial dysfunction is not known, it is plausible that mutation of either inherited or acquired mutations in mitochondrial DNA are responsible [59–61].”
BackgroundCan we image premotor Parkinson disease?
Marek, K., & Jennings, D. (2009) · Neurology · doi:10.1212/wnl.0b013e318198df97 · Cited by 92
Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease
Wood, L. D., Neumiller, J. J., Setter, S. M., & Dobbins, E. K. (2010) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2010.08.002 · Cited by 92 · cited 2×
“Variable degrees of depression have been observed among 40%–70% of the PD patients with a smaller number of PD patients suffering from major depressive disorder [205].”
BackgroundFunctional brain imaging in the differential diagnosis of Parkinson's disease
Piccini, P. P., & Whone, A. L. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00736-7 · Cited by 91 · cited 1×
“PET and SPECT are two methods used to detect pathology in PD patients as these procedures identify and map the changes in the abundance that can be extrapolated as a dopamine synthesis in the caudate putamen [245,268].”
MethodLane, E. L., Winkler, C., Brundin, P., & Cenci, M. A. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.11.011 · Cited by 90 · cited 1×
“Alternatively, another group of studies suggest that graft-induced dyskinesia was due to implantation of serotonergic neurons into the grafts that may have dysfunctional cells that either did not release dopamine regularly or acts as a pseudo-transmitter for serotonergic terminals [234,235].”
BackgroundA double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease
Jankovic, J. J., & Hunter, C. (2002) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(01)00040-2 · Cited by 89 · cited 1×
“Riluzole has glutamate antagonistic properties but did not confer neuroprotection in a small clinical trial conducted in humans [105].”
BackgroundSomatic mitochondrial DNA mutations in single neurons and glia
Cantuti‐Castelvetri, I., Lin, M. T. S., Zheng, K., Keller-McGandy, C. E., Betensky, R. A., Johns, D. R., Beal, M. F., Standaert, D. G., & Simon, D. K. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.11.008 · Cited by 87 · cited 1×
“Although the exact mechanism of mitochondrial dysfunction is not known, it is plausible that mutation of either inherited or acquired mutations in mitochondrial DNA are responsible [59–61].”
BackgroundStatins and stroke: evidence for cholesterol-independent effects
Di Napoli, P. (2002) · European Heart Journal · doi:10.1053/euhj.2002.3236 · Cited by 82 · cited 1×
“It has been few decades since statins have been introduced in the medical field that are known to reduce cholesterol; however, they are also able to prevent inflammation associated with PD by inhibiting pro-inflammatory cytokines and free oxy radical production [178,179].”
BackgroundWood, L. D. (2010) · Drugs & Aging · doi:10.2165/11318330-000000000-00000 · Cited by 82 · cited 1×
“However, we cannot rule out the possibility that not only PD pathology is confined to the degeneration of dopaminergic neurons but also include non-motor such as cognitive impairment, hallucinations and other disturbances due to dysfunction of autonomic nervous system also play major role(s) in the array of impairment…”
BackgroundWilliams, S. S., Williams, J., Combrinck, M., Christie, S., Smith, A. D., & McShane, R. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.155895 · Cited by 81 · cited 1×
“It is important to note that anosmia is not only seen in PD but also prevalent in Lewy body dementia, in AD patients, and in aging population, and could also be side effects of medicines patients consume [263–266].”
BackgroundPramipexole protects against MPTP toxicity in non‐human primates
Iravani, M. M., Haddon, C. O., Cooper, J. M., Jenner, P., & Schapira, A. H. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03625.x · Cited by 81 · cited 1×
“It has been shown that the dopamine receptor agonist can protect against degeneration of TH neurons in both in vitro and in animal models [136–140].”
Goldstein, D. S., & Sewell, L. (2009) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.12.009 · Cited by 77 · cited 1×
“It is important to note that anosmia is not only seen in PD but also prevalent in Lewy body dementia, in AD patients, and in aging population, and could also be side effects of medicines patients consume [263–266].”
BackgroundGene Therapy in Parkinsonʼs Disease: Rationale and Current Status
Feng, L. R., & Maguire-Zeiss, K. A. (2010) · CNS Drugs · doi:10.2165/11533740-000000000-00000 · Cited by 77
Preclinical diagnosis of parkinson’s disease: Are we there yet?
Siderowf, A. D., & Stern, M. B. (2006) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-006-0021-z · Cited by 76 · cited 1×
“To date, although several anti parkinsonian therapeutics showed promise in providing neuroprotective therapy against this devastating debilitating disorder in preclinical animal studies [31–33], none of them has been successful in humans.”
BackgroundImam, S. Z., Trickler, W., Kimura, S., Binienda, Z. K., Paule, M. G., Slikker, W., Li, S., Clark, R. A., & Ali, S. F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065129 · Cited by 76 · cited 1×
“Thus, when we inhibit the c-Abl activity by imatinib/Gleevec [201], nilotinib/Tasigna [202] or bafetinib/INNO-406 [203], they can bring DA to normal amounts and protect the degeneration of TH loss in the midbrain SN of mice [199,200].”
BackgroundSelf-citationNeural grafting in Parkinson’s disease
Lane, E. L., Björklund, A., Dunnett, S. B., & Winkler, C. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)84015-4 · Cited by 74
Parkinson's disease--Part 3: Neuropsychiatric symptoms.
Weintraub, D. A., Comella, C. L., & Horn, S. S. (2008) · PubMed · Cited by 73
Offen, D., Barhum, Y., Levy, Y.-S., Burshtein, A., Panet, H., Cherlow, T., & Melamed, E. (2007) · Springer eBooks · doi:10.1007/978-3-211-73574-9_16 · Cited by 69 · cited 1×
“In a separate study, when BMSCs were infused into an in vivo rat model of PD, those BMSCs synthesized TH and restore motor deficits associated with PD [301].”
BackgroundMadhavan, L., Daley, B. F., Paumier, K. L., & Collier, T. J. (2009) · The Journal of Comparative Neurology · doi:10.1002/cne.22033 · Cited by 69 · cited 1×
“Although a huge effort was made using NSC to generate DA neurons in animal models [288,289], controversy persists regarding neurogenesis in the SVZ in the PD models.”
MethodNonmotor Symptoms in Genetic Parkinson Disease
Kasten, M., Kertelge, L., Brüggemann, N., van der Vegt, J., Schmidt, A., Tadić, V., Buhmann, C., Steinlechner, S., Behrens, M. I., Ramírez, A., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.67.6.670 · Cited by 68 · cited 1×
“However, we cannot rule out the possibility that not only PD pathology is confined to the degeneration of dopaminergic neurons but also include non-motor such as cognitive impairment, hallucinations and other disturbances due to dysfunction of autonomic nervous system also play major role(s) in the array of impairment…”
BackgroundMolecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease
Schapira, A. H. V. (2009) · Neurology · doi:10.1212/wnl.0b013e3181990438 · Cited by 67
Olfaction in Parkinson’s disease: methods of assessment and clinical relevance
Liberini, P., Parola, S., Spano, P., & Antonini, L. (2000) · Journal of Neurology · doi:10.1007/pl00007803 · Cited by 67 · cited 1×
“It is important to note that anosmia is not only seen in PD but also prevalent in Lewy body dementia, in AD patients, and in aging population, and could also be side effects of medicines patients consume [263–266].”
BackgroundMerello, M., Tenca, E., Lloret, S. P., Martín, M. E., Bruno, V., Cavanagh, S., Antico, J., Cerquetti, D., & Leiguarda, R. (2008) · British Journal of Neurosurgery · doi:10.1080/02688690801971667 · Cited by 64 · cited 1×
“Both these procedures may some side effects on communication ability and cognitive deficit [215–223]; although verbal fluency and cognitive deficits were more commonly seen in older patients [222,224].”
BackgroundDisease-modifying drugs and Parkinson's disease
Allain, H., Bentué‐Ferrer, D., & Akwa, Y. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.10.003 · Cited by 61 · cited 1×
“Although it seems that dopamine receptor agonists are neuroprotective, the main shortcoming of the study is that it is not possible to know whether the technique that has been used to evaluate with imaging can correlate neuroprotection of dopaminergic systems and not due to subtle chemical modifications of the radioac…”
Background“Disease-modification” trials in Parkinson disease: Target populations, endpoints and study design
Rascol, O. (2009) · Neurology · doi:10.1212/wnl.0b013e318199049e · Cited by 60
Smeding, H. M. M., Esselink, R. A. J., Schmand, B. A., Koning-Haanstra, M., Nijhuis, I. J. M., Wijnalda, E. M., & Speelman, J. D. (2005) · Journal of Neurology · doi:10.1007/s00415-005-0628-z · Cited by 59
Dopaminergic agonists in Parkinson's disease
Cánovas, A. A., Piudo, R. L., Ruiz-Espiga, P. G., Burguera, J. A., Arillo, V. M. C., Castro, A., Linazasoro, G., del Val, J. L., Vela, L., & Martínez‐Castrillo, J. C. (2014) · Neurología (English Edition) · doi:10.1016/j.nrleng.2011.04.010 · Cited by 58
Impact of STN-DBS on life and health satisfaction in patients with Parkinson's disease
Ferrara, J. M., Diamond, A., Hunter, C., Davidson, A., Almaguer, M., & Jankovic, J. J. (2009) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.184127 · Cited by 58 · cited 1×
“Another recent study suggests that patients who have undergone STN-DBS have a better health-related quality of life; however, occupational function or interpersonal relationships do not improve [232].”
BackgroundPremotor Parkinson's disease: Clinical features and detection strategies
Stephenson, R., Siderowf, A. D., & Stern, M. B. (2009) · Movement Disorders · doi:10.1002/mds.22403 · Cited by 56
Olfaction As a Biomarker in Parkinson‘s Disease
Morley, J. F., & Duda, J. E. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.10.95 · Cited by 55 · cited 1×
“Therefore, olfactory testing used in conjunction with other biomarkers and imaging techniques may serve as a better tool for early detection of PD and thus earlier intervention with neuroprotective therapies before the emergence of extensive dopaminergic neuronal loss and motor symptoms [249,250,267].”
MethodGlial cell participation in the degeneration of dopaminergic neurons in Parkinson's disease.
Hirsch, É. C., Hunot, S., Damier, P., Brugg, B., Faucheux, B. A., Michel, P. P., Ruberg, M., Muriel, M., Prigent, A., & Agid, Y. (1999) · PubMed · Cited by 52
Update on the use of pramipexole in the treatment of Parkinson’s disease
Constantinescu, R. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s2325 · Cited by 52 · cited 1×
“Although such agonist therapies are beneficial, various adverse effects such as hypotension, nausea, hypersexuality, hallucinations, and confusion can occur [130].”
BackgroundLevodopa, Parkinson's Disease, and Hypotension
MCDOWELL, F. H., & LEE, J. E. (1970) · Annals of Internal Medicine · doi:10.7326/0003-4819-72-5-751 · Cited by 51 · cited 1×
“Other well-known side effects of L-DOPA include psychosis, hallucinations and other psychiatric manifestations [124]; and hypotension [125].”
BackgroundInhibition of mixed lineage kinase 3 attenuates MPP+-induced neurotoxicity in SH-SY5Y cells
Mathiasen, J. R., McKenna, B. A., Saporito, M. S., Ghadge, G. D., Roos, R. P., Holskin, B. P., Wu, Z., Trusko, S. P., Connors, T. C., Maroney, A. C., et al. (2004) · Brain Research · doi:10.1016/j.brainres.2003.11.073 · Cited by 50 · cited 1×
“Likewise, CEP-1347 showed promise in animal models [151–153]; however, when evaluated in PD patients in clinical trials, it did not show significant improvement in either resting tremor or cognitive deficit [113].”
BackgroundIssues in neuroprotection clinical trials in Parkinson’s disease
Kieburtz, K. D. (2006) · Neurology · doi:10.1212/wnl.66.10_suppl_4.s50 · Cited by 48 · cited 2×
“Another method has been considered where one group will receive drugs earlier than the other [167,168].”
BackgroundMethodChanges in the glucose transporter of brain capillaries
Harik, S. I. (1992) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y92-252 · Cited by 47
Neuroprotection in Parkinson's disease
Schapira, A. H. V. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70834-x · Cited by 47
Clinical trials for neuroprotection in Parkinson??s disease: overcoming angst and futility?
Hung, A. Y., & Schwarzschild, M. A. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32826388d6 · Cited by 44 · cited 1×
“These in vivo models display significant TH loss in the substantia nigra of the midbrain; however, the amount of time it takes to destroy dopaminergic neurons and pathogenesis is not similar to PD patients [169,170].”
BackgroundFöldes, A., Kádár, K., Kerémi, B., Zsembery, Á., Gyires, K., Zádori, Z., & Varga, G. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160121115210 · Cited by 43 · cited 1×
“Mesenchymal stem cells (MSCs) have many salient features such as they can be easily extracted, cultured and expanded [298,299].”
BackgroundLevodopa: why the controversy?
Agid, Y., Olanow, C. W., & Mizuno, Y. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09733-7 · Cited by 42 · cited 1×
“While replacement of the dopamine deficit with levodopa is an accepted treatment for PD, only ~25% of patients treated with this agent for 5 years continue to enjoy a good response; the remainder suffers from motor fluctuations and involuntary movements [126,127].”
BackgroundRelationship between caffeine intake and Parkinson disease.
Ross, G., Abbott, R., Petrovitch, H., White, L., & Tanner, C. M. (2000) · PubMed · Cited by 42
Parkinson's disease--Part 2: Treatment of motor symptoms.
Weintraub, D. A., Comella, C. L., & Horn, S. S. (2008) · PubMed · Cited by 42
Mathieu, P., Roca, V., Gamba, C., del Pozo, A., & Pitossi, F. J. (2012) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2012.03.004 · Cited by 41 · cited 1×
“MSC derived from the umbilical cord also shows neuroprotective ability in 6-OHDA models of PD [302,303].”
BackgroundGene therapeutic strategies for neurodegenerative diseases.
Baekelandt, V., Strooper, B. D., Nuttin, B., & Debyser, Z. (2000) · PubMed · Cited by 40
The search for biomarkers in Parkinson’s disease: a critical review
Antoniades, C. A., & Barker, R. A. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.12.1841 · Cited by 37 · cited 1×
“An array of different, sensitive omics’ methods has been developed to identify relevant pathways for PD therapeutics [278,279].”
BackgroundHenderson, E. J., Lord, S. R., Close, J., Lawrence, A. D., Whone, A. L., & Ben‐Shlomo, Y. (2013) · BMC Neurology · doi:10.1186/1471-2377-13-188 · Cited by 37
Sniffing out Parkinson Disease: Can Olfactory Testing Differentiate Parkinsonian Disorders?
McKinnon, J. H., Demaerschalk, B. M., Caviness, J. N., Wellik, K. E., Adler, C. H., & Wingerchuk, D. M. (2007) · The Neurologist · doi:10.1097/nrl.0b013e31815a351a · Cited by 36
The preclinical detection of Parkinson's disease: Ready for prime time?
Stern, M. B. (2004) · Annals of Neurology · doi:10.1002/ana.20180 · Cited by 33 · cited 1×
“Varying degrees of olfactory dysfunction have been reported in 50%–90% of PD patients but there is little correlation found between anosmia and the clinical severity of PD [251–254].”
BackgroundMa, Z., Portwood, N., Brodin, D., Grill, V., & Björklund, A. (2007) · Diabetes · doi:10.2337/db06-0322 · Cited by 32 · cited 1×
“It has also been found that pro-inflammatory cytokines such as IL-1beta, IL-6, and TNF-α are increased in the CSF and basal ganglia of PD patients [83–85].”
BackgroundKhan, Z., Ferrari, G. V. D., Kasper, M., Tonge, D., Steiner, J. P., Hamilton, G. S., & Gordon‐Weeks, P. R. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00314-7 · Cited by 30 · cited 1×
“Neuroimmunophilins are proteins that have strong affinity to immunosuppressive drugs and also present in great amount in the brain and induce growth of the neurons [159–161].”
BackgroundStem Cell-Derived Dopamine Neurons for Brain Repair in Parkinson’S Disease
Fricker, R. A., & Gates, M. A. (2010) · Regenerative Medicine · doi:10.2217/rme.10.3 · Cited by 28 · cited 1×
“Thus, human iPSCc can provide a promising source of midbrain DA neurons for cell therapy for PD [297].”
BackgroundAbnormal serum concentrations of proteins in Parkinson’s disease
Goldknopf, I. L., Bryson, J., Strelets, I. O., Quintero, S., Sheta, E. A., Mosqueda, M., Park, H. R., Appel, S. H., Shill, H. A., Sabbagh, M. N., et al. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.08.150 · Cited by 26 · cited 1×
“Additionally, recent evidence has suggested that a complementary system may also play a role in PD pathogenesis as elevated levels of complement proteins in Lewy bodies were observed in PD [86,87].”
BackgroundDevelopment of stem cell-based therapies for Parkinson's disease
Zhu, B., Caldwell, M. A., & Song, B. (2016) · International Journal of Neuroscience · doi:10.3109/00207454.2016.1148034 · Cited by 26 · cited 1×
“Induced pluripotent stem cells (iPSCs) are better sources for PD as these can be derived from the patients, thus eliminating the risk of immune rejection and the requirement of immunosuppressive therapy [293].”
BackgroundTanaka, K., Fujita, N., & Ogawa, N. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02434-x · Cited by 22 · cited 1×
“A study suggests that neuroimmunophilin ligands can protect dopaminergic neurons in the brain in PD models although the mechanism of action was not fully elucidated but the role of neurotrophic factors or glutathione could not be ruled out [162].”
BackgroundContinuous dopaminergic stimulation achieved by duodenal levodopa infusion
Odin, P., Wolters, E. C., & Antonini, A. (2008) · Neurological Sciences · doi:10.1007/s10072-008-1054-7 · Cited by 22 · cited 1×
“Commonly used COMT inhibitors, entacapone and tolcapone, work by inhibiting peripheral degradation of L-DOPA; thus increasing its half-life, stability and bioavailability [131].”
BackgroundTreatment of the nonmotor symptoms of Parkinson disease
Poewe, W. H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.87 · Cited by 19
Targeting the caudal intralaminar nuclei for functional neurosurgery of movement disorders
Benabid, A. L. (2008) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2008.08.020 · Cited by 19 · cited 1×
“Initially, surgeries were targeted to internal globus pallidus (GPi) or the subthalamic nucleus (STN) but most recently deep brain stimulation procedures have been adopted to treat PD patients [18,19].”
BackgroundThe promises of stem cells: stem cell therapy for movement disorders
Mochizuki, H., Choong, C., & Yasuda, T. (2013) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(13)70031-2 · Cited by 18 · cited 1×
“Although a huge effort was made using NSC to generate DA neurons in animal models [288,289], controversy persists regarding neurogenesis in the SVZ in the PD models.”
MethodOlfactory function in essential tremor: A deficit unrelated to disease duration or severity
Hawkes, C. H., Shah, M., & Findley, L. J. J. (2003) · Neurology · doi:10.1212/wnl.61.6.871-a · Cited by 12
Subthalamic Nucleus Deep Brain Stimulation in Parkinson Disease
Cury, R. G., Barbosa, E. R., & de Andrade, D. C. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.0902 · Cited by 8
Therapeutic Strategies for Neurodegenerative Diseases
Fantini, J., & Yahi, N. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800111-0.00014-x · Cited by 7
Cited by
Manoharan, S., Guillemin, G. J., Abiramasundari, R. S., Essa, M. M., Akbar, M., & Akbar, M. D. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/8590578 · Cited by 523
Nakajima, A., & Ohizumi, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143380 · Cited by 235
“The mechanisms that may lead to the degeneration of dopaminergic neurons include oxidative stress, mitochondrial dysfunction, protein aggregation and misfolding, neuroinflammation, excitotoxicity, apoptosis, and loss of trophic factors [54].”
BackgroundEffects of the probiotic formulation SLAB51 in in vitro and in vivo Parkinson’s disease models
Castelli, V., d’Angelo, M., Lombardi, F., Alfonsetti, M., Antonosante, A., Catanesi, M., Benedetti, E., Palumbo, P., Cifone, M. G., Giordano, A., et al. (2020) · Aging · doi:10.18632/aging.102927 · Cited by 162
“In vitro, BDNF counteracted the dopaminergic neurons death, indicating its potential use in the advance of neuroprotective therapeutic approaches for PD [40].”
BackgroundMead, B. P., Kim, N., Miller, G. W., Hodges, D., Mastorakos, P., Klibanov, A. L., Mandell, J. W., Hirsh, J., Suk, J. S., Hanes, J., et al. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b00616 · Cited by 151
Yang, Z., Li, T., Li, S., Wei, M., Qi, H., Shen, B., Chang, R. C.-C., Le, W., & Piao, F. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00460 · Cited by 67
Metadata
- Authors
- Sarkar, S., Raymick, J., & Imam, S.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2016-06-08
- Volume
- 17
- Issue
- 6
- Pages
- 904
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2417001119
- Cited by
- 202
- References
- 301
- FWCI
- 13.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.